FDA Consent Decrees: What Medical Device Manufacturers Must Know to Stay Compliant

What Is an FDA Consent Decree and Why Should Device Manufacturers Care?

An FDA consent decree is not a warning. It is not a suggestion. It is a federal court order that can halt manufacturing operations, freeze product distribution, and impose third-party oversight that costs millions of dollars per year. For a medical device startup or a growing mid-size company, a consent decree is often an existential event.

Yet many founders and even seasoned quality leaders treat consent decrees as something that only happens to large legacy manufacturers. That assumption is wrong, and it is dangerous. The FDA has pursued consent decrees against companies of every size when systemic quality system failures go uncorrected. Understanding how they arise and how to prevent them is not optional for any company with a device on the U.S. market.

How FDA Consent Decrees Actually Happen: The Escalation Path

Consent decrees do not appear out of nowhere. They are the end result of a regulatory escalation that typically follows this sequence:

• FDA inspections and Form 483 observations: Inspectors document objectionable conditions under 21 CFR Part 820 (Quality System Regulation, now transitioning to alignment with ISO 13485 under the 2024 Quality Management System Regulation, or QMSR). These are observations, not violations, but they demand serious written responses within 15 business days.
• Warning letters: If 483 responses are inadequate or violations persist, FDA issues a warning letter under 21 CFR 7.45. This becomes public record and signals that the agency views the company as a significant compliance risk.
• Injunctive action: When warning letters fail to drive correction, FDA refers the matter to the Department of Justice, which files for a permanent injunction in federal district court. The resulting consent decree is negotiated or imposed.

The critical inflection point is almost always the 483 response. Companies that respond defensively, minimally, or with incomplete corrective action plans hand the FDA the evidence it needs to escalate. Companies that respond with rigor, root cause analysis, and verifiable corrective actions close the loop before it becomes a warning letter.

What a Consent Decree Actually Costs You

Beyond the obvious reputational damage, the operational and financial burden is severe. Under a typical consent decree, a manufacturer may be required to:

• Cease manufacturing and distribution of affected products until FDA-certified third-party experts certify compliance.
• Retain and fund an independent expert panel, often called a 'consent decree consultant,' to audit every aspect of the quality system -- at the company's expense.
• Submit detailed remediation reports on a schedule FDA controls, not you.
• Pay substantial fines, which under the Federal Food, Drug, and Cosmetic Act can reach thousands of dollars per day of violation.
• Recall distributed product if the agency determines patient safety risk warrants it.

For a startup pre-revenue or a company with concentrated product lines, this is not a recoverable situation without significant restructuring, investor intervention, or acquisition. Even for larger companies, consent decrees have lasted a decade or more.

The Most Common Quality System Failures That Lead to Consent Decrees

Based on FDA enforcement history and publicly available warning letters, the violations that most frequently escalate to injunctive action cluster around specific subsystems of 21 CFR Part 820 (and its successor, 21 CFR Part 820 as amended under the QMSR finalized in February 2024):

• CAPA (Corrective and Preventive Action): Under 21 CFR 820.100, CAPA must identify root causes and verify effectiveness. Companies routinely close CAPAs without demonstrated effectiveness checks, which inspectors flag as systemic failure.
• Design Controls: Under 21 CFR 820.30, design history files must be complete and traceable. Missing design verification and validation records are among the most cited observations in FDA-483s preceding warning letters.
• Process Validation: Under 21 CFR 820.75, manufacturers must validate processes whose results cannot be fully verified by inspection. Sterilization, molding, and software processes are frequent gaps.
• Complaint Handling and MDR Reporting: Failure to submit Medical Device Reports under 21 CFR Part 803 when complaints meet reportable thresholds is a direct patient safety issue FDA treats with zero tolerance.
• Management Responsibility: Under 21 CFR 820.20, executive leadership must establish quality policy, conduct management reviews, and ensure resources. When FDA sees that quality is siloed from leadership, it signals systemic dysfunction.

Proactive Compliance: What Actually Prevents a Consent Decree

Prevention is not about paperwork volume. It is about building a quality system that generates real data, responds to real signals, and demonstrates real leadership commitment. Here is what separates companies that survive inspections from those that do not:

Treat 483 Observations as Your Final Warning

Every Form 483 observation your company receives should be treated with the urgency of a warning letter. Assign a responsible owner, conduct documented root cause analysis using structured methodologies such as fishbone diagrams or 5-Why analysis, and submit a written response that commits to specific, measurable, time-bound corrective actions. Vague commitments and templated responses do not satisfy investigators.

Conduct Rigorous Internal Audits Before FDA Does

Under 21 CFR 820.22, internal audits are a regulatory requirement -- but the companies that avoid escalation treat them as a genuine discovery exercise, not a compliance checkbox. Audit against both the regulation and FDA's own guidance documents, including the 2023 FDA guidance on 'Inspections of Medical Device Manufacturers' and publicly issued warning letters, which telegraph exactly what investigators are looking for in your industry segment.

Invest in Post-Market Surveillance Infrastructure

A robust complaint handling system, MDR decision trees, and trend analysis capability are not administrative burdens. They are your early warning system. If your complaint handling process cannot distinguish a reportable event from a non-reportable one within defined timeframes, you have a gap that FDA will find.

Align Leadership with Quality Objectives

The QMSR's alignment with ISO 13485:2016 places even greater emphasis on top management accountability. Quality cannot be something that lives only in the QA department. When FDA investigators see management review records that are cursory, or when they interview executives who cannot speak to quality metrics, the observation writes itself.

If You Are Already Under a Warning Letter

Speed and substance matter more than anything else at this stage. Engage experienced regulatory counsel immediately. Do not attempt to negotiate with the FDA through a junior regulatory coordinator or without outside expertise. The response strategy, the third-party audit selection, and the remediation sequencing all affect whether FDA accepts your corrective action plan or refers the matter for injunctive action. There is very little margin for error once a warning letter is on the table.

The Bottom Line

An FDA consent decree is preventable. It requires building quality systems that work, leadership that is genuinely engaged, and a compliance posture that treats regulatory requirements as the floor, not the ceiling. The companies that avoid consent decrees are not lucky -- they are disciplined, well-advised, and proactive about identifying gaps before FDA does.

At ADB Consulting and CRO Inc., Andre Butler and the team work directly with medical device startups and established manufacturers to build inspection-ready quality systems, respond to FDA 483 observations and warning letters, and develop regulatory strategies that protect your business at every stage of the product lifecycle. If you are unsure whether your quality system would hold up under an FDA inspection today, that uncertainty is itself the answer.

Book a free discovery call with our team at adbccro.com and get an honest assessment of where your compliance program stands before the FDA determines that for you.